Low cholesterol in dialysis patients causal factor for mortality or an effect of confounding?
|
|
- Mavis Amy Joseph
- 5 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2011) 26: doi: /ndt/gfr008 Advance Access publication 28 February 2011 Low cholesterol in dialysis patients causal factor for mortality or an effect of confounding? Michal Chmielewski 1, *, Marion Verduijn 2, *, Christiane Drechsler 3, Bengt Lindholm 4, Peter Stenvinkel 5, Boleslaw Rutkowski 1, Elisabeth W. Boeschoten 6, Raymond T. Krediet 7 and Friedo W. Dekker 2 1 Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland, 2 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, 3 Department of Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany, 4 Division of Renal Medicine and Baxter Novum, Karolinska Institutet, Stockholm, Sweden, 5 Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden, 6 Hans Mak Institute, Naarden, The Netherlands and 7 Department of Nephrology, Academic Medical Centre, Amsterdam, The Netherlands Correspondence and offprint requests to: Michal Chmielewski; chmiel@gumed.edu.pl *Both authors equally contributed to this work. Abstract Background. The association between cholesterol and mortality is reversed in end-stage renal disease (ESRD). This phenomenon has many potential explanations, one of them being time discrepancy of competing risks. It states that hypercholesterolaemia is beneficial only in the short term, while it worsens survival over a long-term interval. It is also proposed that the reversed relationship between cholesterol and outcome is due to confounding protein energy wasting. The aim of the study was to verify the hypothesis of time discrepancy of competing risks in 1191 incident dialysis patients (Netherlands Cooperative Study on the Adequacy of Dialysis). Methods. Conditional Cox proportional hazards analysis was applied, where associations between cholesterol level and short-term versus long-term mortality were being compared. Furthermore, to evaluate associations between cholesterol and outcome free from confounding, Mendelian randomization was introduced, using apolipoprotein E (apoe) genotype. Results. Hypercholesterolaemia (>240 mg/dl) was associated with improved 5-year survival when compared to the low cholesterol group (<200 mg/dl), hazard ratio (HR) ¼ 0.62 ( ), P < However, conditional Cox proportional hazards analysis revealed that the reverse association between high cholesterol and all-cause mortality was evident only during the first year of follow-up, HR ¼ 0.43 ( ), P < 0.01, and then, gradually, declined. The apoe genotype significantly affected cholesterol concentration. The e2 carriers, associated with low cholesterol, had significantly increased risk of non-cardiovascular mortality. Conclusions. Reverse association between cholesterol concentration and mortality in dialysis patients is short-termed, consistent with the hypothesis of time discrepancy of competing risks. Low cholesterol appeared to affect noncardiovascular mortality in ESRD patients free from confounders. Keywords: cholesterol; dialysis; Mendelian randomization; reverse epidemiology Introduction Patients with end-stage renal disease (ESRD) are at increased risk of mortality, both from cardiovascular and non-cardiovascular causes [1]. There are numerous risk factors that contribute to this condition, including: oxidative stress, calcium phosphate disorders, anaemia, inflammation, protein energy wasting (PEW), lipoprotein disturbances, etc. However, some of these risk factors seem to have an opposite effect on outcome compared to what has been observed in the general population. This reverse association between a risk factor and mortality is especially prominent for cholesterol levels. Several studies have shown that low cholesterol is related to poor outcome in ESRD subjects, while hypercholesterolaemia seems to be protective [2 5]. There are many potential explanations for this, so-called reverse epidemiology phenomenon. Most of them regard inflammation, PEW and other comorbidities as factors responsible for low cholesterol levels and, at the same time, responsible for increased mortality of ESRD patients [4, 6]. Another hypothesis, termed time discrepancy of competing risks, discerns two types of risk factors for increased mortality, short-term and long-term [7]. While hypercholesterolaemia is a significant risk factor for atherosclerosis progression and mortality over a long period of time (decades), as seen in the general population, inflammation and PEW are short-term killers (months years). As the mortality rate for ESRD patients is much higher than for the general population, they do not live long enough for the long-term risk factors to manifest their influence. To add to this confusion, there are also theories of a direct Ó The Author Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oup.com
2 3326 M. Chmielewski et al. beneficial impact of increased lipid concentrations on survival in chronic disease states, like ESRD [8]. Whether low cholesterol is a causal risk factor in the ESRD population or is merely a risk marker is difficult to clarify on the basis of observational evaluations. There is, however, a way to substantiate a potential causal role of low cholesterol by the use of a genetic variant related to cholesterol levels in a, so-called Mendelian randomization approach [9]. The gene for apolipoprotein E (apoe), which is polymorphic with three common alleles (e2, e3 and e4), affects cholesterol concentration, with e2 being associated with the lowest and e4 with the highest cholesterol level. Due to random assortment of genes during gamete formation, independent of environmental factors, with the use of apoe variants, the association between cholesterol levels and mortality can be estimated free from confounding and reverse causation. Thus, low cholesterol could be regarded as a causal mortality risk factor if the genetic variant encoding for low cholesterol (e2) is associated with worse outcome. Mendelian randomization approach has been initially proposed by Katan for cancer patients [10] and could similarly be applied in ESRD subjects [9]. The aim of this study was to elucidate the issue of the apparent association between low cholesterol and mortality. The first part of the evaluation implements conditional Cox proportional hazards analysis in order to verify the hypothesis of time discrepancy of competing risks [11]. The second part utilizes associations between genetic variants of apoe and cholesterol levels to get insight into the causative role of low cholesterol using Mendelian randomization. Materials and Methods Patients This study was performed in the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD). This is a multicentre prospective follow-up study in which ESRD patients from 38 Dutch dialysis centres are included at the start of chronic dialysis treatment. All local medical ethics committees approved the study and all patients gave informed consent before inclusion. Eligibility criteria were 18 years and no previous renal replacement therapy. Details on the design and methods of NECO- SAD are described elsewhere [12]. In the present study, patients were included with a minimal follow-up of 3 months since the start of dialysis (baseline of the analysis). From a total group of 1615 patients, we excluded subjects with statin use since, in our opinion, the impact of statins on cholesterol blurred the association between mortality and cholesterol as a marker. This resulted in a cohort of 1269 patients; for 78 of them, no cholesterol measurement was available, so a group of 1191 patients was used for evaluation. The second part of the study, aiming at apoe polymorphism evaluation, included 563 patients, of the 1191 subjects characterized above, who had started dialysis in 1 of the 23 centres that approved DNA analysis. All patients were followed until the date of death or censoring, i.e. kidney transplantation, transfer to a non-participating dialysis centre, withdrawal from the study or end of the follow-up period, with a maximum follow-up of 5 years since start of dialysis. Demographic and clinical data At the start of dialysis, data were collected on age, gender, primary kidney disease, comorbidity and dialysis modality. At 3 months after dialysis initiation, medication use was recorded and subjective global assessment (SGA) was performed. Blood samples were obtained at this time point. Total cholesterol level was measured routinely at the local laboratories, while highsensitive C-reactive protein (hscrp) was measuredcentrally at the University Hospital Aachen, Germany. Clinical definitions Primary kidney disease and causes of death were classified according to the code of the European Renal Association European Dialysis and Transplant Association (ERA EDTA) [13]. Cardiovascular mortality was defined as death due to the following causes: myocardial ischaemia and infarction, hyperkalaemia, hypokalaemia, cardiac arrest, heart failure, fluid overload, cerebrovascular accident, haemorrhage from a ruptured vascular aneurysm, mesenteric infarction and cause of death uncertain/unknown. All other causes of death were designated as non-cardiovascular mortality. The most prevalent were infections, malignancies, cachexia and refusal of further treatment. Patients with a history of angina pectoris, myocardial infarction, cardiac insufficiency or who had peripheral vessel damage or a cerebrovascular accident were classified as having cardiovascular disease. Patients with an hscrp value of >10 mg/l were considered as inflamed. This cutoff point was previously used to divide patients in a group with or without a chronic inflammatory state [14], and in ESRD patients, this cutoff point for C-reactive protein (CRP) level has been shown to be the best with regard to the prediction of survival [15]. Patients with a score of 1 5 on a 7-point SGA were diagnosed as having PEW [16]. ApoE genotyping ApoE genotyping was performed in 434 patients with a DNA sample by polymerase chain reaction (PCR) analysis using primers: ApoE forward 5#-AGA-CGC-GGG-CAC-GGC-TGT-CCA-AGG-A-3# and ApoE reverse 5#-ATA-AAT-ATT-ATA-AAA-TAT-AAA-TAA-CAG-AAT-TCG-CCC- CGG-CCT-GGT-ACA-C-3#. The reaction mixture included 30 pmol of each primer, 100 ng genomic DNA, 0.2 mmol/l of each deoxyribonucleotide triphosphate dntp (Pharmacia), 5 ll 103 PCR buffer (Qiagen), 10% dimethyl sulphoxide, 1.5 U Taq polymerase (Qiagen) in a total volume of 50 ll. Amplification was performed for 35 cycles of 1 min at 95 C, 1 min at 60 C and 2 min at 72 C with an initial denaturation period of 5 min. After the last cycle, a final extension period of 5 min at 72 C min was used. A PCR product of 267 bp was generated. Some 35 ll of PCR products were digested with the restriction enzyme CfoI according to the recommendations of the supplier (Promega). Thereafter, fragments were separated on a 5% agarose gel and stained with ethidium bromide. The e2 allele was characterized by the presence of 104, 91, 38, 18 and 16 bp fragments. The e3allele was characterized by the presence of 91, 56, 48, 38, 18 and 16 bp fragments. The e4 allele was characterized by the presence of 72, 56, 48, 38, 19, 18 and 16 bp fragments. For 129 patients without a DNA sample, apoe phenotypes were determined by isoelectric focusing of delipidated serum samples followed by immunoblotting with polyclonal anti-apoe antiserum as described by Havekes et al. [17]. Statistical analysis All values are expressed as percentages (for categorical variables), mean and SD, unless otherwise indicated. Differences among the groups were analysed by one-way analysis of variance for continuous variables and a chisquare test for categorical variables. For comparisons according to cholesterol level, patients were grouped following the National Cholesterol Education Program - Adult Treatment Panel III guidelines [18] into: low (desirable), with a total cholesterol concentration defined as <200 mg/ dl; borderline, where values varied between 200 and 240 mg/dl and high, with cholesterol >240 mg/dl. We used Kaplan Meier survival analysis to obtain survival curves for each cholesterol category. Hazard ratios (HRs) were calculated by Cox proportional hazards analysis using the low cholesterol group as a reference category. Multivariate adjustment was performed for the following potential confounding factors: age, gender, diabetes mellitus, dialysis modality, inflammation, PEW, haemoglobin, use of erythropoiesis-stimulating agents (ESA), dialysis adequacy (Kt/V) and smoking. We assessed the time-stratified effect of baseline cholesterol on mortality using conditional Cox regression analysis [11] in order to evaluate the influence of duration of follow-up on the association between cholesterol level and mortality. In this analysis, the HRs for mortality during the first year of dialysis were compared to the HRs for mortality during the second year of therapy, conditional upon having survived the first year. Similar evaluation was performed for the Years 3 5, conditional upon having survived the previous period. Therefore, for the long-term survival analysis, we considered only these patients who survived past the first 2 years of dialysis treatment. For the genetic part of the analysis, patients were grouped according to apoe genotypes. The apoe2 group consisted of e2 carriers (e2/2 and e2/3) and the apoe4 of e4 carriers(e3/4 and e4/4), while the reference group (apoe3) consisted of e3/3 homozygotes. Twelve patients with e2/4 genotype
3 Low cholesterol in dialysis patients 3327 were excluded from the analysis since in these patients, the two alleles affected cholesterol concentration in opposite directions. This resulted in 551 patients for further evaluation. Differences in baseline characteristics among the genotype groups as well as the association between apoe genotype and mortality were evaluated as above. Statistical analyses were performed using statistical software SPSS version (SPSS Inc., Chicago, IL). Results Basic characteristics of patients according to their cholesterol concentration are presented in Table 1. Their primary kidney disease was renal vascular disease in 17% of cases, diabetic nephropathy in 14% and glomerulonephritis in 13%. For the remaining 56%, ESRD was due to other diseases or unknown causes. The majority of the 1191 patients presented with low (desirable) cholesterol values (55%). Borderline values were observed in 27% of subjects, while 18% of patients displayed high cholesterol concentration according to NCEP ATP III. Patients with low cholesterol levels were older and had a higher prevalence of cardiovascular disease, inflammation and PEW. Male gender and haemodialysis treatment also prevailed in this group. The follow-up time was 5 years with a median observation time of 2.3 years. During this time period, 438 subjects died, 208 of them due to cardiovascular causes. Kaplan Meier analysis showed a considerable association between cholesterol levels and mortality, with low (desirable) cholesterol predicting poor outcome (Figure 1). Indeed, in Cox proportional hazards analysis, hypercholesterolaemia was associated with a significantly decreased risk for all-cause mortality; crude HR ¼ 0.62 ( ), P < Conditional Cox proportional hazards analysis revealed that the protective association between high cholesterol and survival was evident only during the first year of follow-up; crude HR ¼ 0.43 ( ), P < Afterward, this relationship was substantially weaker, with HR ¼ 0.67 ( ), P ¼ 0.16 in the second year and HR ¼ 0.73 ( ), P ¼ 0.12 during the following 3 years (Table 2). After adjustment for potential confounders (age, gender, diabetes mellitus, dialysis modality, inflammation and PEW), the time discrepancy of competing risks became even more evident: hypercholesterolaemia seemed Table 1. Characteristics of the incident dialysis patients included in the study subdivided according to cholesterol concentration a to confer an apparent benefit on outcome only in the first year, HR: 0.47 ( ), P ¼ 0.12, while the HRs were much closer to 1 (representing no benefit) in subsequent years (Table 2). Further adjustment for haemoglobin level, use of ESA, dialysis adequacy (Kt/V) and smoking did not alter the results significantly. In further analysis, cardiovascular and non-cardiovascular mortality were evaluated separately as they showed different patterns of association with cholesterol level. For cardiovascular mortality, the association between cholesterol and 5-year outcome did not reach statistical significance; crude HR ¼ 0.75 ( ), P ¼ For non-cardiovascular mortality, it was considerably stronger; crude HR ¼ 0.53 ( ), P < 0.01, although substantially attenuated following adjustment for age, gender, diabetes mellitus, dialysis modality, inflammation and PEW; HR ¼ 0.76 ( ), P ¼ In conditional Cox analysis, cardiovascular mortality was significantly affected by cholesterol concentration only during the first year of dialysis therapy (Table 3). During the following years of observation, this association disappeared. For non-cardiovascular mortality, benefit of hypercholesterolaemia was observed across the whole follow-up period. The association between cholesterol and noncardiovascular mortality was, however, deeply affected by adjustment for confounders. From the second year onwards, the relationship vanished following adjustment for comorbidities, inflammation and PEW (Table 4). It is worth mentioning that there was only one death due to infectious causes in the high cholesterol group, during the first 2 years of dialysis treatment. General characteristics of the patients grouped according to their apoe genotype are presented in Table 5. The e2 carriers were slightly older than the other two groups of patients, while e4 carriers were less inflamed and less wasted than e2 subjects. Similarly to the general population, cholesterol concentration was significantly lower in patients with the e2 variant. Since low cholesterol level was associated with poor outcome in the first part of the analysis, we tested whether the e2 variant would be related to increased mortality. The median follow-up time was 2.4 years; during this time period, 199 patients died, 91 due to cardiovascular Cholesterol concentration (mg/dl) <200 Low b (N ¼ 657) Borderline b (N ¼ 325) >240 High b (N ¼ 209) P-value Age, years 60.4 (16.4) 58.4 (15.7) 57.3 (14.4) <0.01 Gender, % male <0.01 CVD, % <0.01 DM, % Inflamed, % (CRP > 10 mg/l) Serum albumin (g/l) 36.0 ( ) 37.1 ( ) 37.4 ( ) <0.01 Wasted, % (SGA 5) <0.01 Dialysis modality, % HD <0.01 a CVD, cardiovascular disease; DM, diabetes mellitus, HD, haemodialysis. b According to NCEP ATP III [18].
4 3328 M. Chmielewski et al. causes. Although no difference in all-cause mortality risk was observed among the apoe groups, the e2 variant was associated with substantially increased risk of noncardiovascular mortality; HR ¼ 1.61 ( ), P ¼ 0.04, while the risk of cardiovascular mortality was decreased in this patient group; HR: 0.70 ( ), P ¼ 0.26 (Figure 2). Adjustment for age resulted in a slight decrease of the risk for both non-cardiovascular and cardiovascular mortality, with HRs being 1.38 and 0.60, respectively. Discussion Fig. 1. Five-year patient survival in each of cholesterol concentration groups. Table 2. Conditional Cox proportional hazards analysis for all-cause mortality a All patients (N ¼ 1191) In the present study, we have shown that the reverse association between cholesterol concentration and mortality in dialysis patients is short-termed, which is consistent with Cholesterol category Low (N ¼ 657) Borderline (N ¼ 325) High (N ¼ 209) First year (121 events) Crude HR ( ); P ¼ ( ); P < 0.01 Adjusted ( ); P ¼ ( ); P ¼ 0.11 Adjusted ( ); P ¼ ( ); P ¼ 0.12 Adjusted ( ); P ¼ ( ); P ¼ 0.05 Second year (106 events) Crude HR ( ); P ¼ ( ); P ¼ 0.16 Adjusted ( ); P ¼ ( ); P ¼ 0.54 Adjusted ( ); P ¼ ( ); P ¼ 0.83 Adjusted ( ); P ¼ ( ); P ¼ 0.74 Following 3 years (212 events) Crude HR ( ); P ¼ ( ); P ¼ 0.12 Adjusted ( ); P ¼ ( ); P ¼ 0.51 Adjusted ( ); P ¼ ( ); P ¼ 0.78 Adjusted ( ); P ¼ ( ); P ¼ 0.95 a Adjusted 1 for age, gender, diabetes mellitus and dialysis modality; adjusted 2 above 1 inflammation (hscrp > 10 mg/l) and PEW (SGA 1 5) and adjusted 3 above 1 dialysis adequacy (Kt/V), use of ESA, haemoglobin and smoking. Table 3. Conditional Cox proportional hazards analysis for cardiovascular mortality a All patients (N ¼ 1191) Cholesterol category Low (N ¼ 657) Borderline (N ¼ 325) High (N ¼ 209) First year (51 events) Crude HR ( ); P ¼ ( ); P ¼ 0.07 Adjusted ( ); P ¼ ( ); P ¼ 0.17 Adjusted ( ); P ¼ ( ); P ¼ 0.52 Adjusted ( ); P ¼ ( ); P ¼ 0.17 Second year (51 events) Crude HR ( ); P ¼ ( ); P ¼ 0.85 Adjusted ( ); P ¼ ( ); P ¼ 0.72 Adjusted ( ); P ¼ ( ); P ¼ 0.88 Adjusted ( ); P ¼ ( ); P ¼ 0.58 Following 3 years (107 events) Crude HR ( ); P ¼ ( ); P ¼ 0.68 Adjusted ( ); P ¼ ( ); P ¼ 0.76 Adjusted ( ); P ¼ ( ); P ¼ 0.98 Adjusted ( ); P ¼ ( ); P ¼ 0.99 a Adjusted 1 for age, gender, diabetes mellitus and dialysis modality; adjusted 2 above 1 inflammation (hscrp > 10 mg/l) and PEW (SGA 1 5) and adjusted 3 above 1 dialysis adequacy (Kt/V), use of ESA, haemodialysis and smoking.
5 Low cholesterol in dialysis patients 3329 Table 4. Conditional Cox proportional hazards analysis for non-cardiovascular mortality a All patients (N ¼ 1191) Cholesterol category Low (N ¼ 657) Borderline (N ¼ 325) High (N ¼ 209) First year (70 events) Crude HR ( ); P ¼ ( ); P ¼ 0.05 Adjusted ( ); P ¼ ( ); P ¼ 0.36 Adjusted ( ); P ¼ ( ); P ¼ 0.16 Adjusted ( ); P ¼ ( ); P ¼ 0.15 Second year (55 events) Crude HR ( ); P ¼ ( ); P ¼ 0.12 Adjusted ( ); P ¼ ( ); P ¼ 0.25 Adjusted ( ); P ¼ ( ); P ¼ 0.88 Adjusted ( ); P ¼ ( ); P ¼ 0.95 Following 3 years (105 events) Crude HR ( ); P ¼ ( ); P ¼ 0.05 Adjusted ( ); P ¼ ( ); P ¼ 0.22 Adjusted ( ); P ¼ ( ); P ¼ 0.70 Adjusted ( ); P ¼ ( ); P ¼ 0.78 a Adjusted 1 for age, gender, diabetes mellitus and dialysis modality; Adjusted 2 above 1 inflammation (hscrp > 10 mg/l) and PEW (SGA 1 5) and Adjusted 3 above 1 dialysis adequacy (Kt/V), use of ESA, haemoglobin and smoking. Table 5. Characteristics of the incident dialysis patients included in the study subdivided according to the apoe gene isoform a ApoE variant e2 (N ¼ 100) e3 (N ¼ 322) e4 (N ¼ 129) P-value Cholesterol, mg/dl (45.7) (48.8) (50.7) <0.01 Age, years 62.1 (15.6) 59.4 (16.1) 56.6 (15.3) 0.04 Gender, % male CVD, % DM, % Inflamed, % (CRP > 10 mg/l) Wasted, % (SGA 5) Dialysis modality, % HD a CVD, cardiovascular disease; DM, diabetes mellitus, HD, haemodialysis. Fig. 2. HRs for the association between the apoe genotype and 5 years mortality in 551 patients. the hypothesis of time discrepancy of competing risks. Moreover, in the studied cohort, subjects with genetically determined lower cholesterol concentrations were at increased risk of non-cardiovascular mortality. Before discussing these results, some caveats of the study should be mentioned. First, the sample size was rather small, especially for the genetic part of the study. This was associated with the relatively low number of events, which resulted in wide confidence intervals in survival analyses. Nevertheless, NECOSAD is one of the largest European cohorts of incident dialysis patients. Another potential limitation might be that for predicting outcome in the general population, total cholesterol is inferior to low-density lipoprotein cholesterol or apob/apoa-i. Unfortunately, these lipid parameters, as well as high-density lipoprotein cholesterol, were not collected in the NECOSAD cohort. The most persuasive explanation for the observed reverse association between low cholesterol levels and mortality in ESRD is that the phenomenon is due to confounding by inflammation and/or PEW. This hypothesis was supported by Liu et al. [4] who showed that low cholesterol predicted mortality only in patients with low serum albumin levels (i.e. inflamed and/or wasted). The subgroup of patients with normal albumin concentrations displayed a typical association between high cholesterol and poor outcome. However, a subsequent study [5] in a similar cohort of patients did not confirm the results of Liu
6 3330 M. Chmielewski et al. et al. [4]. Moreover, large randomized clinical trials in ESRD patients showed no benefit of cholesterol reduction despite clear effects of statin therapy on outcome in the general population [19, 20]. Since the issue remained opened, theories on a direct beneficial impact of increased cholesterol concentration started to rise. A theory put forward by Rauchhaus et al. [21] stated that in certain clinical conditions low cholesterol might actually be harmful. This hypothesis has been supported by results of experimental studies showing that lipoproteins are capable of binding bacterial lipopolysaccharide or endotoxins [22 24]. Thus, the endotoxin lipoprotein theory might be applicable in dialysis patients, who are at increased risk of infections because of immunological disturbances and the dialysis procedure itself. One of the most convincing theories explaining the phenomenon of reverse epidemiology is the time discrepancy of competing risks hypothesis. It has been proposed by Kalantar-Zadeh et al. [7] and states that hypercholesterolaemia appears beneficial only in the short-term, while over a long follow-up period, it becomes detrimental. As mentioned, it is based on the fact that life expectancy for the general population is much longer than for dialysis patients. Whereas subjects from the general population live long enough for high cholesterol levels to have an impact on atherosclerosis and cardiovascular complications, dialysis patients have a life expectancy comparable to patients with colon cancer. Therefore, in the short-term, ESRD patients die because of disorders associated with inflammation and/ or PEW, and we can observe an association between low cholesterol and mortality. We have previously verified this hypothesis in a cohort of Swedish incident dialysis patients [25] showing that whereas increased apob/apoa-1 ratio predicted short-term (first year) survival, it predicted longterm (next 3 years) mortality. In order to verify whether observed associations are causal or simply due to confounders, we have introduced adjustments to survival analyses. Indeed, adding consecutive potential confounders into Cox analysis resulted in an attenuation of presented relationships. However, especially in the first year of follow-up, even extensive adjustment did not level the associations completely. It might be due to residual confounders, the one that we did not account for, or to potential direct effect of cholesterol on outcome. To clarify this issue, we also analysed our data using the Mendelian randomization approach with the apoe genotype as an instrumental variable. The use of this method to draw causal inferences from observational studies is becoming increasingly common [26]. Our analysis showed that e2 carriers (low cholesterol) had a slightly decreased risk of cardiovascular mortality, which seems logical since low cholesterol is typically associated with slower atherosclerosis progression. However, as the risk of noncardiovascular mortality was increased in e2 carriers, low cholesterol might directly increase the risk of noncardiovascular complications in ESRD patients. This supports the endotoxin lipoprotein hypothesis stating that decreased lipoprotein concentrations are associated with impaired defense against bacterial endotoxins. Indeed, only one patient died of infectious causes in the high cholesterol group during the first 2 years of dialysis therapy. Conclusions In conclusion, reversed association between cholesterol concentration and mortality is mainly short-termed, which is consistent with the hypothesis of time discrepancy of competing risks. It is, to a significant extent, a result of confounding factors such as age, comorbidities, inflammation and PEW. Our results also suggest the existence of a causal relationship between low cholesterol and non-cardiovascular mortality. Acknowledgements. This study was supported by grants from the Dutch Kidney Foundation (E.018) and the Dutch National Health Insurance Board (OG97/005). The nursing staffs of the participating dialysis centres are gratefully acknowledged for collecting most of the clinical data. The authors also wish to thank the staff of the NECOSAD trial office for their assistance in the logistics of this study. Conflict of interest statement. None declared. References 1. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: Iseki K, Yamazato M, Tozawa M et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: Kilpatrick RD, McAllister CJ, Kovesdy CP et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: Fleischmann EH, Bower JD, Salahudeen AK. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J 2001; 47: Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: Chmielewski M, Carrero JJ, Nordfors L et al. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008; 21: Zoccali C, Testa A, Spoto B et al. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis 2006; 47: Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986; 1: Dekker FW, de Mutsert R, van Dijk PC et al. Survival analysis: timedependent effects and time-varying risk factors. Kidney Int 2008; 74: Muntinghe FL, Verduijn M, Zuurman MW et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009; 20: van Dijk PC, Jager KJ, de Charro F et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16: Grootendorst DC, de Jager DJ, Brandenburg VM et al. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant 2007; 22: Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62:
7 Low cholesterol in dialysis patients Steiber A, Leon JB, Secker D et al. Multicenter study of the validity and reliability of subjective global assessment in the hemodialysis population. J Ren Nutr 2007; 17: Havekes LM, de Knijff P, Beisiegel U et al. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987; 28: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: Flegel WA, Baumstark MW, Weinstock C et al. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61: Levine DM, Parker TS, Donnelly TM et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90: Read TE, Grunfeld C, Kumwenda ZL et al. Triglyceride-rich lipoproteins prevent septic death in rats. JExpMed1995; 182: Chmielewski M, Carrero JJ, Qureshi AR et al. Temporal discrepancies in the association between the apob/apoa-i ratio and mortality in incident dialysis patients. J Intern Med 2009; 265: Davey Smith G, Ebrahim S. Mendelian randomization : can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1 22 Received for publication: ; Accepted in revised form:
Excess mortality due to interaction between proteinenergy wasting, inflammation and cardiovascular disease in chronic dialysis patients
7 Excess mortality due to interaction between proteinenergy wasting, inflammation and cardiovascular disease in chronic dialysis patients R. de Mutsert D.C. Grootendorst J. Axelsson E.W. Boeschoten R.T.
More informationNutritional predictors of mortality in prevalent peritoneal dialysis patients
Regular paper Vol. 63, No 1/2016 111 115 http://dx.doi.org/10.18388/abp.2015_1070 Nutritional predictors of mortality in prevalent peritoneal dialysis patients Sylwia Malgorzewicz 1 *, Michal Chmielewski
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationConcern about the decreasing use of peritoneal dialysis
Page 1 of 8 Peritoneal Dialysis International Peritoneal Dialysis International, Vol. 30, pp. doi: 10.3747/pdi.2008.00277 0896-8608/10 $3.00 +.00 Copyright 2010 International Society for Peritoneal Dialysis
More informationHow is the dialysis patient different?
How is the dialysis patient different? Mihály Tapolyai, MD, FASN, FACP Fresenius Medical Care SOTE, Budapest; Hungary Minneapolis VAMC, Minneapolis, MN; USA How is the dialysis patient different? Dialysis
More informationMalnutrition and inflammation in peritoneal dialysis patients
Kidney International, Vol. 64, Supplement 87 (2003), pp. S87 S91 Malnutrition and inflammation in peritoneal dialysis patients PAUL A. FEIN, NEAL MITTMAN, RAJDEEP GADH, JYOTIPRAKAS CHATTOPADHYAY, DANIEL
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationTRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA
& TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia
More informationPeritoneal Dialysis Adequacy: Not Just Small- Solute Clearance
Advances in Peritoneal Dialysis, Vol. 24, 2008 Rajesh Yalavarthy, Isaac Teitelbaum Peritoneal Dialysis Adequacy: Not Just Small- Solute Clearance Two indices of small-solute clearance, Kt/V urea and creatinine
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More information1. Reggie J. Divina, M.D. (1) 2. Fe S. Felicilda, M.D., DPBCN (1,2) 3. Rufino E. Chan, M.D. (1) 4. Luisito O. Llido, M.D.
82 TITLE: Nutritional status of hemodialysis patients in the Philippines: a cross sectional survey in four out- patient dialysis centers Submitted: January 10, 2010 Posted: August 30, 2010 AUTHOR(S) 1.
More informationThe association of lipid levels with mortality in patients on chronic peritoneal dialysis
Nephrol Dial Transplant (2006) 21: 2881 2892 doi:10.1093/ndt/gfl272 Advance Access publication 30 May 2006 Original Article The association of lipid levels with mortality in patients on chronic peritoneal
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationEnd stage renal disease and Protein Energy wasting
End stage renal disease and Protein Energy wasting Dr Goh Heong Keong MBBS,MRCP(UK) www.passpaces.com/kidney.htm Introduction Chronic kidney disease- increasing health burden in many countries. The estimated
More informationThe association between lipid abnormalities (higher total
Inverse Association between Lipid Levels and Mortality in Men with Chronic Kidney Disease Who Are Not Yet on Dialysis: Effects of Case Mix and the Malnutrition- Inflammation-Cachexia Syndrome Csaba P.
More informationImproved survival of type 2 diabetic patients on renal replacement therapy in Finland
Nephrol Dial Transplant (2010) 25: 892 896 doi: 10.1093/ndt/gfp555 Advance Access publication 21 October 2009 Improved survival of type 2 diabetic patients on renal replacement therapy in Finland Marjo
More informationPredictive Factors for Withdrawal from Peritoneal Dialysis: A Retrospective Cohort Study at Two Centers in Japan
Advances in Peritoneal Dialysis, Vol. 33, 2017 Yasuhiro Taki, 1 Tsutomu Sakurada, 2 Kenichiro Koitabashi, 2 Naohiko Imai, 1 Yugo Shibagaki 2 Predictive Factors for Withdrawal from Peritoneal Dialysis:
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationDiagnostic methods 2: receiver operating characteristic (ROC) curves
abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager
More informationAJNT. Original Article
. 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationAetiology versus Prediction - correct for Confounding? Friedo Dekker ERA-EDTA Registry / LUMC
Aetiology versus Prediction - correct for Confounding? Friedo Dekker ERA-EDTA Registry / LUMC Aetiology Study effect of a risk factor on an outcome Consider potential confounding: other risk factor for
More informationTitle: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study.
Manuscript type: Invited Commentary: Title: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study. Authors: David C Wheeler 1 and Bertram
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationmediators might be causal in the accelerated
Elevated Serum Macrophage Migration Inhibitory Factor (MIF) Concentrations in Chronic Kidney Disease (CKD) Are Associated with Markers of Oxidative Stress and Endothelial Activation Annette Bruchfeld,
More informationSimilar Survival on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis in a Large Prospective Cohort
Similar Survival on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis in a Large Prospective Cohort Wieneke Marleen Michels,* Marion Verduijn, Elisabeth Wilhelmina Boeschoten,
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21978 holds various files of this Leiden University dissertation. Author: Goeij, Moniek Cornelia Maria de Title: Disease progression in pre-dialysis patients:
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationAspetti nutrizionali nel paziente in emodialisi cronica
Aspetti nutrizionali nel paziente in emodialisi cronica Enrico Fiaccadori enrico.fiaccadori@unipr.it Università degli Studi di Parma Agenda Diagnosis of protein-energy wasting (PEW) in ESRD on HD Epidemiology
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationSupplementary Document
Supplementary Document 1. Supplementary Table legends 2. Supplementary Figure legends 3. Supplementary Tables 4. Supplementary Figures 5. Supplementary References 1. Supplementary Table legends Suppl.
More informationChapter 15: Causes of Death on Renal Replacement Therapy
Chapter 15: Causes of Death on Renal Replacement Therapy Summary Cardiovascular disease is the most common cause of death in the renal population and is most evident in diabetics. Patients on renal replacement
More informationIntroduction. Keywords: Infrainguinal bypass; Prognosis; Haemorrhage; Anticoagulants; Antiplatelets.
Eur J Vasc Endovasc Surg 30, 154 159 (2005) doi:10.1016/j.ejvs.2005.03.005, available online at http://www.sciencedirect.com on Risk of Major Haemorrhage in Patients after Infrainguinal Venous Bypass Surgery:
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationCHAPTER 12 CARDIOVASCULAR MORTALITY OF PATIENTS WHO COMMENCE DIALYSIS WITHOUT CLINICAL EVIDENCE OF CARDIOVASCULAR DISEASE
CHPTER CRDIOVSCULR MORTLITY OF PTIENTS WHO COMMENCE DILYSIS WITHOUT CLINICL EVIDENCE OF CRDIOVSCULR DISESE Matthew Roberts Kevan Polkinghorne Stephen McDonald Francesco Ierino CRDIOVSCULR MORTLITY NZDT
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19985 holds various files of this Leiden University dissertation. Author: Appeldoorn- de Jager, Dina Jezina (Dinanda) van Title: Progression of CKD form
More informationHypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients
Kidney International, Vol. 61 (2002), pp. 1887 1893 Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients KUNITOSHI ISEKI, MASANOBU YAMAZATO, MASAHIKO TOZAWA,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29973 holds various files of this Leiden University dissertation. Author: Meuwese, Christiaan Lucas Title: Nontraditional cardiovascular risk factors in
More informationPeritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
Int Urol Nephrol (2015) 47:1739 1744 DOI 10.1007/s11255-015-1087-9 NEPHROLOGY - ORIGINAL ARTICLE Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease Magdalena Jankowska
More informationEconomic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T
Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationc Tuj1(-) apoptotic live 1 DIV 2 DIV 1 DIV 2 DIV Tuj1(+) Tuj1/GFP/DAPI Tuj1 DAPI GFP
Supplementary Figure 1 Establishment of the gain- and loss-of-function experiments and cell survival assays. a Relative expression of mature mir-484 30 20 10 0 **** **** NCP mir- 484P NCP mir- 484P b Relative
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationNutrition in hemodialysis patients with focus on Intradialytic Parenteral Nutrition (IDPN)
Nutrition in hemodialysis patients with focus on Intradialytic Parenteral Nutrition (IDPN) Enrico Fiaccadori enrico.fiaccadori@unipr.it Acute and Chronic Renal Failure Unit Medicine & Surgery Dept. Parma
More informationOUT OF DATE. Coronary artery, cerebrovascular and peripheral vascular disease
19..23 NEPHROLOGY 2010; 15, S19 S23 doi:10.1111/j.1440-1797.2010.01227.x Coronary artery, cerebrovascular and peripheral vascular disease Date written: December 2008 Final submission: March 2009nep_1227
More informationVitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients
In The Name of GOD Vitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients Authors & Affiliations: 1-jamal hallajzadeh; Maraghe University of
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationORIGINAL RESEARCH. 224 Journal of Renal Nutrition, Vol 20, No 4 (July), 2010: pp
ORIGINAL RESEARCH Independent and Joint Associations of Nutritional Status Indicators With Mortality Risk Among Chronic Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationBlood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ
1 Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ 2016.033440 Dear Editor, Editorial Committee and Reviewers Thank you for your appreciation
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationThe outcomes of continuous ambulatory and automated peritoneal dialysis are similar
http://www.kidney-international.org & 2009 International Society of Nephrology see commentary on page 12 The outcomes of continuous ambulatory and automated peritoneal dialysis are similar Rajnish Mehrotra
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationMeeting the Guidelines for End-of-Life Care
Advances in Peritoneal Dialysis, Vol. 22, 2006 Gillian Brunier, David M.J. Naimark, Michelle A. Hladunewich Meeting the Guidelines for End-of-Life Care The number of patients initiating dialysis in most
More informationWhy has the gross mortality of dialysis patients increased in Japan?
Kidney International, Vol. 57, Suppl. 74 (2000), pp. S-60 S-65 Why has the gross mortality of dialysis patients increased in Japan? MORTALITY TAKASHI AKIBA, SHIGERU NAKAI, TORU SHINZATO, CHIKAO YAMAZAKI,
More informationThe EQUAL study: a European study in chronic kidney disease stage 4 patients
Nephrol Dial Transplant (2012) 27 (Supple 3): iii27 iii31 doi: 10.1093/ndt/gfs277 Advance Access publication 4 July 2012 Editorial Review The EQUAL study: a European study in chronic kidney disease stage
More informationAdvanced IPD meta-analysis methods for observational studies
Advanced IPD meta-analysis methods for observational studies Simon Thompson University of Cambridge, UK Part 4 IBC Victoria, July 2016 1 Outline of talk Usual measures of association (e.g. hazard ratios)
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationEffects of Body Size and Body Composition on Survival in Hemodialysis Patients
J Am Soc Nephrol 14: 2366 2372, 2003 Effects of Body Size and Body Composition on Survival in Hemodialysis Patients SRINIVASAN BEDDHU,* LISA M. PAPPAS, NIRUPAMA RAMKUMAR, and MATTHEW SAMORE *Renal Section,
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationEFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey
EFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey Chair: Walter H. Hörl, Vienna, Austria Wojciech Zaluska, Lublin, Poland Prof Ercan Ok Division
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationThe effect of joint exposures: examining the presence of interaction
http://www.kidney-international.org & 2009 International Society of Nephrology abc of epidemiology The effect of joint exposures: examining the presence of interaction Renée de Mutsert 1, Kitty J. Jager
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationAssociation of the ApoE gene polymorphism and dietary factors with cerebral infarction and circulating lipid concentrations
Association of the ApoE gene polymorphism and dietary factors with cerebral infarction and circulating lipid concentrations H.-Q. Yan, Y. Yuan, P. Zhang, Z. Huang, L. Chang and Y.-K. Gui Department of
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationA loss-of-function variant in CETP and risk of CVD in Chinese adults
A loss-of-function variant in CETP and risk of CVD in Chinese adults Professor Zhengming CHEN Nuffield Dept. of Population Health University of Oxford, UK On behalf of the CKB collaborative group (www.ckbiobank.org)
More informationAssociation between causes of peritoneal dialysis technique failure and all-cause mortality
www.nature.com/scientificreports Received: 27 September 2017 Accepted: 21 February 2018 Published: xx xx xxxx OPEN Association between causes of peritoneal dialysis technique failure and all-cause mortality
More informationSerum Albumin as Predictor of Nutritional Status in Patients with ESRD
CJASN epress. Published on June 21, 2012 as doi: 10.2215/CJN.10251011 Article Serum Albumin as Predictor of Nutritional Status in Patients with ESRD Thiane Gama-Axelsson, Olof Heimbürger, Peter Stenvinkel,
More informationAccelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus
Kidney International, Vol. 68 (2005), pp. 2368 2374 Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus LARA B. PUPIM, OLOF HEIMBÜRGER, ABDUL RASHID QURESHI, T.
More informationMETABOLISM AND NUTRITION WITH PD OBESITY. Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle
METABOLISM AND NUTRITION WITH PD OBESITY Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle 1 Body Size in Patients New to Dialysis United States Body Mass Index, kg/m2 33 31
More informationStefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K.
Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece Passive, degenerative accumulation process of Ca ++ /P +++ without treatment options Active, complex, condition:
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationChapter 6: Mortality. Introduction 2016 USRDS ANNUAL DATA REPORT VOLUME 2 ESRD IN THE UNITED STATES
Chapter 6: Mortality In 2014, adjusted mortality rates for ESRD, dialysis, and transplant patients, were 136, 166, and 30, per 1,000 patient-years, respectively. By dialysis modality, mortality rates were
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationSummary HTA. HTA-Report Summary
Summary HTA HTA-Report Summary Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events Schnell-Inderst
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationTransplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation Titte R Srinivas, MD, FAST Medical Director, Kidney and Pancreas Transplant Programs Objectives: Describe trends
More informationChapter 10: Factors which may influence cardiovascular disease blood pressure and serum cholesterol
Chapter 10: Factors which may influence cardiovascular disease blood pressure and serum cholesterol Summary. Blood pressure returns to the Renal Registry continue to be poor from some centres.. In England
More informationHasan Fattah 3/19/2013
Hasan Fattah 3/19/2013 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationKrediet slide di 18
1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More information